People searching for a ghk-cu peptide injection dosage per day are usually looking for a number, but the honest answer is that no such number exists in peer-reviewed human research. GHK-Cu (glycyl-L-histidyl-L-lysine, bound to copper) is a naturally occurring tripeptide with real, decades-old evidence behind it, and almost all of that evidence is for the topical, cosmetic route, not injection.
The Compound Universe Take: There is no FDA-approved or clinically standardized injection dosage for GHK-Cu. The peptide’s actual evidence base is topical: a small human trial and multiple lab reviews support copper tripeptide serums for skin appearance, while injectable GHK-Cu remains an unresolved FDA compounding category with no controlled human dosing studies as of July 2026. Numbers circulating online for “mg per day” are vendor protocols, not clinical findings.
Researching a specific compound? See the GHK-Cu research overview for the full evidence summary, or check peptide legal status by compound before assuming any product is compliant.
What GHK-Cu actually is
GHK-Cu is not a novel lab invention. It is a naturally occurring peptide-copper complex found in human plasma that declines steadily with age, which is part of why researchers first connected it to tissue repair and skin aging [1]. In its synthetic form it shows up on cosmetic ingredient labels as “copper tripeptide-1,” almost always in a topical serum or cream.
That distinction matters more than most listicles admit. Copper is a required cofactor for collagen and elastin cross-linking, and GHK-Cu appears to work partly by delivering and directing that copper at the cellular level [4]. The injectable version sold by some research-chemical vendors is the same molecule, but it sits in a completely different evidence and regulatory lane, which is the actual reason a reliable “per day” dose does not exist for it.
| Attribute | Topical / cosmetic GHK-Cu | Injectable GHK-Cu |
|---|---|---|
| Typical use | Serums, creams (copper tripeptide-1) | Compounded or research-chemical vials |
| Evidence tier | Human pilot + lab/animal reviews | Preclinical only; no controlled human dosing trials located |
| Standard “per day” dose | Product-label concentration, not a dose | Not established in published research |
| FDA status | Regulated as a cosmetic ingredient | Unsettled 503A bulk-substance category, under review |
The evidence, sorted by route of administration
Topical GHK-Cu: the route with an actual human trial
The strongest human data point is a randomized study of 13 patients who used a copper tripeptide complex after CO2 laser resurfacing. The GHK-Cu group showed no statistically significant advantage over controls in erythema resolution or objective wrinkle scores at 12 weeks, but patient-reported satisfaction was significantly higher with GHK-Cu (P = .04) [2]. That is a modest, honest result: real signal on subjective skin appearance, not a dramatic clinical difference on hard measures.
Supporting that, laboratory and review work shows GHK-Cu stimulates fibroblast production of collagen and elastin and influences gene-expression patterns tied to tissue repair [3][4]. Most of this supporting mechanism work is in-vitro and animal-derived; the 2006 laser-resurfacing study remains one of the few controlled human trials specific to topical GHK-Cu.
Injectable GHK-Cu: evidence and regulation both unsettled
Injectable GHK-Cu is marketed by some compounding pharmacies and research-chemical sellers for wound healing and anti-aging, but no controlled human dosing trial for injectable GHK-Cu turned up in this research. The daily “mg” figures posted on peptide-vendor and dosing-calculator sites are commercial protocols, not results from published clinical studies, and none of them should be read as a verified standard.
The regulatory picture underlines why. GHK-Cu for injectable use was placed on the FDA’s Category 2 list in 2023, the category the agency reserves for substances it judges to carry significant safety risk if compounded. That nomination was withdrawn in April 2026, and the compound is now slated for a fresh Pharmacy Compounding Advisory Committee review before the end of February 2027 [5]. In plain terms, injectable GHK-Cu has moved between “restricted” and “under review” within the last three years, which is not a foundation for a fixed per-day number.
Read this before you look for a protocol: This page is a research summary, not medical advice or a dosing guide. Compound Universe does not provide injection instructions or per-day protocols for GHK-Cu or any peptide. Injectable GHK-Cu’s FDA compounding category has changed multiple times since 2023 and is under active review; verify current status with a licensed provider before assuming any product is legal or safe. Topical GHK-Cu is a cosmetic ingredient and is not FDA-evaluated for anti-aging claims.
| Question | What the record shows | Evidence tier |
|---|---|---|
| Does topical GHK-Cu affect skin? | Increases collagen/elastin markers in lab work; modest human satisfaction signal | Human pilot + in-vitro |
| Is there a proven injection dose? | No controlled human dosing study located | Not established |
| Is injectable GHK-Cu FDA-approved? | No; compounding category under PCAC review through Feb 2027 | Regulatory / in flux |
| Is topical GHK-Cu legal to sell? | Yes, as a cosmetic ingredient (copper tripeptide-1) | Regulatory |
Key takeaways
- No verified per-day injection dosage for GHK-Cu exists in published human research, despite the numbers on vendor and calculator sites.
- Topical GHK-Cu (copper tripeptide-1) is the route with actual human trial data, including a 13-patient randomized study on laser-resurfaced skin [2].
- GHK-Cu’s core mechanism involves copper delivery to fibroblasts, supporting collagen and elastin synthesis at the cellular level [3][4].
- Injectable GHK-Cu’s FDA compounding category has shifted since 2023 and is under fresh review through early 2027, not a settled status [5].
- Any source offering a fixed “mg per day” injection protocol is describing a vendor practice, not a clinical finding.
Frequently asked questions
What is the standard GHK-Cu peptide injection dosage per day?
There is no clinically established standard. No controlled human trial testing daily injectable GHK-Cu doses was located in this research; figures posted online come from compounding pharmacies or vendors, not peer-reviewed studies.
Is injectable GHK-Cu FDA-approved?
No. Injectable GHK-Cu is not an FDA-approved drug. Its compounding category has moved between restricted and under-review status since 2023, with further review scheduled before February 2027.
Is topical GHK-Cu the same thing as injectable GHK-Cu?
The peptide itself is the same molecule, but the evidence and regulatory pictures are different. Topical GHK-Cu is an established cosmetic ingredient with human trial data; injectable GHK-Cu has no controlled human dosing studies behind it.
Does GHK-Cu actually work for skin?
The evidence is modest and honest, not dramatic. Lab and animal work shows it supports collagen and elastin production, and one small human trial found higher patient satisfaction with topical GHK-Cu, though not a statistically significant objective advantage [2][4].
Can I buy GHK-Cu legally?
Topical GHK-Cu (copper tripeptide-1) is legal and common in cosmetic products. Injectable GHK-Cu sits in a shifting FDA compounding category, so its legal status depends on the seller, the route, and your jurisdiction; check current status before purchasing.
Where can I find real research on GHK-Cu instead of dosage charts?
Start with peer-reviewed reviews on tissue remodeling and skin regeneration mechanisms [1][3][4], and treat any site offering a specific “mg per day” injection number as a commercial claim rather than a cited clinical result.
GHK-Cu sits at the intersection of copper biology and skin science, where its role as a copper-carrier tripeptide connects to collagen synthesis, fibroblast activity, and the broader category of cosmetic peptides like matrixyl and argireline that target visible aging through different mechanisms; Compound Universe tracks GHK-Cu against both the published research and the FDA’s compounding-list status, because for this compound the regulatory record moves almost as often as the lab findings do.
If you came here looking for a ghk-cu peptide injection dosage per day, the most accurate answer is that one has not been established in controlled human research, and the compound’s best-supported use today remains topical, not injectable.
Related reading: Compound Universe’s topical peptide research guides
References
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88. PMID 18644225. DOI 10.1163/156856208784909435.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin. Arch Facial Plast Surg. 2006;8(4):252-259.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.
- Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020. PMC8789089.
- FDA interim 503A Bulk Drug Substances list, Category 1/Category 2 status changes for GHK-Cu (injectable and non-injectable nominations withdrawn April 2026; PCAC review scheduled before end of February 2027), per regulatory analysis published by Frier Levitt, 2026. (VERIFY exact FDA docket/Federal Register citation directly at fda.gov before publish.)